(Q54329423)

27 May 2018

title

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. (English)

1 reference

27 May 2018

1 reference

7

Rino Rappuoli

1 reference

27 May 2018

8

Mariagrazia Pizza

1 reference

27 May 2018

Philipp Oster

6

Philipp Oster

1 reference

27 May 2018

Alessia Biolchi

2

Alessia Biolchi

1 reference

27 May 2018

Marzia Monica Giuliani

1

Marzia M Giuliani

1 reference

27 May 2018

Francesca Ferlicca

4

Francesca Ferlicca

1 reference

27 May 2018

Davide Serruto

3

Davide Serruto

1 reference

27 May 2018

author name string

Kay Vienken

5

1 reference

27 May 2018

John Donnelly

9

1 reference

27 May 2018

language of work or name

English

0 references

publication date

21 May 2010

1 reference

27 May 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

27 May 2018

volume

28

1 reference

27 May 2018

issue

31

1 reference

27 May 2018

page(s)

5023-5030

1 reference

27 May 2018

Human immunity to the meningococcus. II. Development of natural immunity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Meningococcal polysaccharide-protein conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

NadA, a novel vaccine candidate of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

NadA diversity and carriage in Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Multilocus sequence typing for global surveillance of meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

Structural and functional characterization of a recombinant PorB class 2 protein from Neisseria meningitidis. Conformational stability and porin activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.014

10.1016/J.VACCINE.2010.05.014

7 January 2021

Identifiers

DOI

1 reference

27 May 2018

PubMed ID

20493284

1 reference

27 May 2018